Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week from RheumNow.com. This week focuses on parodoxical psoriasis, scleroderma outcomes and subsets, and alopecia areata therapy.
Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95.
The hallmark of systemic sclerosis is scleroderma, but less than 10% of SSc patients have sine scleroderma (ssSSc). A EUSTAR database review compared the manifestations and outcomes of ssSSC to limited cutaneous SSc and diffuse cutaneous SSc.
Dr. John Cush RheumNow
3 years 2 months ago
Mirikizumab, an anti-IL-23 MAb, shown to be effective in phase 2 trial in ulcerative colitis. 1281 Pts: mirikizumab > placebo group w/ remission at wk 12 (24% vs 13%, P<0.001) & after re-randomization & maintenance @wk 40l (50% vs 25%, P<0.001) https://t.co/9ZPsRCDhJc https://t.co/jrJvzAhyWY
Dr. John Cush RheumNow
3 years 2 months ago
Metanalysis of JAK inhib in Alopecia Areata: 7 RCTs &1710 patients shows JAK inhibitors yielded > 50% hair regrowth (OR 5.28) or > 90% improvement (OR 8.15) vs PBO. Oral JAK inhibitors were better than topical (latter = PBO). https://t.co/J9kGh89aEi https://t.co/QbMY1m4NQe
Dr. John Cush RheumNow
3 years 2 months ago
Congratulations to Dr Stephan Maier who has been appointed as the Executive Director of EULAR. https://t.co/K7LCWT8Q6l https://t.co/xXV9ROFXqq
Dr. John Cush RheumNow
3 years 2 months ago
A 35 yr old daughter of one of your Seropos. #RA patients shows up with finger arthralgias, +ACPA 200 IU and questions about if will she get RA. Here's a Survey for Rheumatologists and what you would do:https://t.co/lt38vJM6T2
Dr. John Cush RheumNow
3 years 2 months ago
FDA Delays Bimekizumab Decision, Again
UCB, the maker of the IL-17 A/F inhibitor bimekizumab (BMK), has announced that the FDA decision on BMK use in adults with moderate to severe plaque psoriasis has been delayed until the 3rd quarter of 2023.
https://t.co/u3wZp2xain https://t.co/pEldK1grb9
Dr. John Cush RheumNow
3 years 2 months ago
Gut Microbiome Alterations in Lupus Patients
Recurrent bouts of systemic lupus erythematosus, marked by the body’s immune system attack of its own tissues, closely tracked with measurable upticks in growth in the gut of a certain species of bacteria.
https://t.co/eGk4EQsVES https://t.co/PiFKxJWD13
A randomised controlled trial including 347 participants with lower back or neck pain found there was no benefit of taking opioid pain relievers compared to placebo.
Dr. John Cush RheumNow
3 years 2 months ago
Taiwan claims data analysis of 1,830 scleroderma (SSc) pts & 27,981 controls showed increased incidence of SSc hospitalized w/ heart failure of 3.5%, 5.3%, & 9.7% (at 3, 5, 10 yrs). SSc patients had an increased risk of HF (adjusted HR 3.26) https://t.co/4WcHfiTJVF https://t.co/rW3J5aQdlS
Dr. John Cush RheumNow
3 years 2 months ago
Paradoxical Psoriasis in Kids Taking TNF Inhibitors
A multicenter cohort study reported a large cohort of pediatric patients receiving TNF inhibitor therapy complicated by psoriasis, regardless of treatment indication or the specific TNF inhibitor.
https://t.co/f1KmICaGNF https://t.co/N0jxIJbv7Q
Dr. John Cush RheumNow
3 years 2 months ago
High BMI Increases Arthritis Risk
Obesity carries many risks, now a new study in Arthritis & Rheumatology shows that higher BMI increases the risk for several rheumatic diseases, especially in women for both gout and psoriatic arthropathy.
https://t.co/9IRBAYT1F7 https://t.co/2GX3S3OnX7
Dr. John Cush RheumNow
3 years 2 months ago
RheumNow LIVE VOTE Survey:
What do you need to better manage pre-clinical (at-risk) Rheumatoid arthritis? Please vote here >>https://t.co/lt38vJMEIA
